Serum protein electrophoresis pattern alterations on lipidoses patients

2020 ◽  
Vol 129 (2) ◽  
pp. S100-S101
Author(s):  
Laura López de Frutos ◽  
Elena García-González ◽  
Jorge J. Cebolla ◽  
Carlos Lahoz ◽  
Beatriz García-Rodríguez ◽  
...  
Author(s):  
Tiene Rostini ◽  
Coriejati Rita

Serum protein electrophoresis pattern can assist in diagnosis of liver disease, hematological disorders, renal disorders andgastrointestinal disease. Measurement of total protein level in the serum cannot detect any disorders in patient with normal limit ofserum total protein level. The aim of this study; was to evaluate the serum protein electrophoresis pattern in patient with normal limitsof serum protein level. This research was carried out by descriptive retrospective study using the electrophoresis data from patients’medical record at the Clinical Pathology Department, Dr. Hasan Sadikin General Hospital Bandung. The data of serum electrophoresis (bySebia gel electrophoresis) were grouped based on disease or disorders, and confirmed with the diagnosis derived from patient’s medicalrecord. Inclusion criteria of samples if ; the electrophoresis data were available, serum total protein level within normal limits (6.4–8.3mg/dL), and the data of electrophoresis taken from medical record were taken from August 2006 until August 2008. The result foundso far was, there were 240 data of electrophoresis from patients with serum protein level within normal limits (6.4–8.3 mg/dL). theinterpretation of electrophoresis consist of: 1) inflammation (149 patients; 62.2% ; sensitivity 83.7%, specificity 86,5%) 2) Cirrhosis(46 patients ; 19.2% ; sensitivity 87.5% ; specificity 88.4%) 3) Nephritic syndrome (15 patients ; 6.2%; sensitivity 53%; specificity96.9% 4) Monoclonal gammophaty (15 patients(6.2% ; sensitivity 80% ; specificity 98.7%) 5) Normal pattern in 15 patient (6.2%).This study found abnormal serum protein electrophoresis pattern in the condition of inflammation, Cirrhosis, Nephritic Syndrome, andMonoclonal gammophaty. It can be concluded that many disorders could be detected in patient with serum protein level within normallimits such as: inflammation, cirrhosis, nephritis syndrome and monoclonal gammophaty by abnormal electrophoresis pattern


2021 ◽  
pp. 337-343
Author(s):  
Eugenie Mok ◽  
Ka Wai Kam ◽  
Anthony J. Aldave ◽  
Alvin L. Young

A 65-year-old man presented with bilateral, painless, progressive blurring of vision over 9 years. Slit-lamp examination revealed bilateral subepithelial corneal opacities in clusters located at the mid-periphery. Anterior segment optical coherence tomography, in vivo confocal microscopy (IVCM), serum protein electrophoresis, and molecular genetic testing were performed to evaluate the cause of corneal opacities. Anterior segment optical coherence tomography revealed a band-like, hyperreflective lesion in the Bowman layer and anterior stroma of both corneas. IVCM revealed hyperreflective deposits in the epithelium, anterior stroma, and endothelium. Serum protein electrophoresis identified the presence of paraproteins (immunoglobulin kappa), and molecular genetic testing revealed absence of mutations in the transforming growth factor beta-induced gene (<i>TGFBI</i>) and collagen type XVII alpha 1 gene (<i>COL17A1</i>). The ocular diagnosis of paraproteinemic keratopathy eventually led to a systemic diagnosis of monoclonal gammopathy of undetermined significance by our hematologist/oncologist. Paraproteinemic keratopathy is a rare differential diagnosis in patients with bilateral corneal opacities and therefore may be misdiagnosed as corneal dystrophy or neglected as scars. In patients with bilateral corneal opacities of unknown cause, serological examination, adjunct anterior segment imaging, and molecular genetic testing play a role in establishing the diagnosis.


2021 ◽  
pp. e00200
Author(s):  
J.M. Gastélum-Cano ◽  
J. Fragoso-Flores ◽  
V.M. Noffal-Nuño ◽  
M. Deffis-Court

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0200347 ◽  
Author(s):  
Emma H. Hooijberg ◽  
Michele Miller ◽  
Carolyn Cray ◽  
Peter Buss ◽  
Gerhard Steenkamp ◽  
...  

Author(s):  
Rachel D Wheeler ◽  
Micsha V Costa ◽  
Asante Crichlow ◽  
Fenella Willis ◽  
Yasmin Reyal ◽  
...  

Multiple myeloma is a haematological cancer caused by malignant plasma cells in the bone marrow that can result in organ dysfunction and death. Recent novel treatments have contributed to improved survival rates, including monoclonal antibody therapies that target the CD38 protein on the surface of plasma cells. Anti-CD38 therapies are IgG kappa monoclonal antibodies that are given in doses high enough for the drug to be visible on serum protein electrophoresis as a small paraprotein. We present a case where isatuximab, the most recent anti-CD38 monoclonal antibody to be approved for treatment of myeloma, obscured the patient’s paraprotein on gel immunofixation, so that complete remission could not be demonstrated. This was resolved using the isatuximab Hydrashift assay. The interference on gel immunofixation was unexpected because isatuximab migrated in a position distinct from the patient’s paraprotein on capillary zone electrophoresis. We demonstrate the surprising finding that isatuximab migrates in a different position on gel electrophoresis compared to capillary zone electrophoresis. It is vital that laboratories are aware of the possible interference on electrophoresis from anti-CD38 monoclonal antibody therapies, and are able to recognise these drugs on protein electrophoresis. The difference in isatuximab’s electrophoretic mobility on capillary and gel protein electrophoresis makes this particularly challenging. Laboratories should have a strategy for alternative analyses in the event that the drugs interfere with assessment of the patient’s paraprotein.


Sign in / Sign up

Export Citation Format

Share Document